Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which chemo combo slows advanced colon cancer best?

NCT ID NCT00642603

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests two different drug combinations as a first treatment for people with metastatic colorectal cancer—cancer that has spread beyond the colon or rectum. Participants receive capecitabine (Xeloda) plus bevacizumab (Avastin), and are randomly assigned to also get either irinotecan or oxaliplatin for the first several cycles, followed by maintenance therapy. The goal is to see which combination better delays cancer progression and to compare their safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
capecitabine (Xeloda) combined with bevacizumab (Avastin), plus either irinotecan or oxaliplatin
What this could lead to
If successful, this could help identify a more effective first-line chemotherapy combination to slow cancer progression in people with metastatic colorectal cancer.
What could go wrong
This is a small phase 2 trial, so results may not be definitive. The added drugs can cause side effects like diarrhea, nerve damage, or bleeding, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

41 people

The number who actually took part.

Start date

May 2008

Finished

Mar 2009

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients, ≥18 years of age * Histologically confirmed adenocarcinoma of colon or rectum, with unresectable metastatic or locally advanced disease * ≥1 measurable target lesion * Ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 Exclusion Criteria: * Prior systemic therapy for advanced or metastatic disease * History of another malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of the cervix * Clinically significant cardiovascular disease * Current or recent use of full dose oral warfarin or full dose parenteral anticoagulants or thrombolytic agents * Chronic daily treatment with \>325 mg/day aspirin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

Contacts and locations

Locations

  • Study site

    PARK Springs, Arizona, 71913, United States

  • Study site

    Sedona, Arizona, 86336, United States

  • Study site

    Tucson, Arizona, 85712, United States

  • Study site

    Anaheim, California, 92801, United States

  • Study site

    Colton, California, 92324, United States

  • Study site

    Greenbrae, California, 94904, United States

  • Study site

    Loma Linda, California, 92354, United States

  • Study site

    Modesto, California, 95355, United States

  • Study site

    Montebello, California, 90640, United States

  • Study site

    Pomona, California, 91767, United States

  • Study site

    Sacramento, California, 95816, United States

  • Study site

    Norwich, Connecticut, 06360, United States

  • Study site

    Waterbury, Connecticut, 06708, United States

  • Study site

    Lake Worth, Florida, 33431, United States

  • Study site

    Miami Shores, Florida, 33179, United States

  • Study site

    New Port Richey, Florida, 34655, United States

  • Study site

    Ocala, Florida, 34474, United States

  • Study site

    Ocoee, Florida, 34761, United States

  • Study site

    Marietta, Georgia, 30060, United States

  • Study site

    Niles, Illinois, 60714, United States

  • Study site

    Paducah, Kentucky, 42002, United States

  • Study site

    Alexandria, Louisiana, 71301, United States

  • Study site

    Baltimore, Maryland, 21204, United States

  • Study site

    Baltimore, Maryland, 21237, United States

  • Study site

    Westminster, Maryland, 21157, United States

  • Study site

    Pittsfield, Massachusetts, 01201, United States

  • Study site

    Worcester, Massachusetts, 01608, United States

  • Study site

    Kalamazoo, Michigan, 49048, United States

  • Study site

    Duluth, Minnesota, 55805, United States

  • Study site

    Jefferson City, Missouri, 65109, United States

  • Study site

    Great Falls, Montana, 59405, United States

  • Study site

    Las Vegas, Nevada, 89109, United States

  • Study site

    Neptune City, New Jersey, 07754, United States

  • Study site

    Albuquerque, New Mexico, 87102, United States

  • Study site

    Albuquerque, New Mexico, 87131-5636, United States

  • Study site

    Santa Fe, New Mexico, 87505, United States

  • Study site

    Brooklyn, New York, 11219, United States

  • Study site

    Huntington Station, New York, 11746, United States

  • Study site

    Durham, North Carolina, 27710, United States

  • Study site

    Hickory, North Carolina, 28602, United States

  • Study site

    Canton, Ohio, 44718, United States

  • Study site

    Eugene, Oregon, 97401-8122, United States

  • Study site

    Ephrata, Pennsylvania, 17522, United States

  • Study site

    Langhorne, Pennsylvania, 19047, United States

  • Study site

    Philadelphia, Pennsylvania, 19102, United States

  • Study site

    Scranton, Pennsylvania, 18510, United States

  • Study site

    Charleston, South Carolina, 29403-5740, United States

  • Study site

    Charleston, South Carolina, 29406, United States

  • Study site

    Florence, South Carolina, 29506, United States

  • Study site

    Sumter, South Carolina, 29150, United States

  • Study site

    Chattanooga, Tennessee, 37404, United States

  • Study site

    Cookeville, Tennessee, 38501, United States

  • Study site

    Nashville, Tennessee, 37203, United States

  • Study site

    Amarillo, Texas, 79106, United States

  • Study site

    Arlington, Texas, 76014, United States

  • Study site

    Beaumont, Texas, 77702-1449, United States

  • Study site

    Bedford, Texas, 76022, United States

  • Study site

    Carrollton, Texas, 75010, United States

  • Study site

    Corpus Christi, Texas, 78412, United States

  • Study site

    Dallas, Texas, 75230, United States

  • Study site

    Dallas, Texas, 75231, United States

  • Study site

    Dallas, Texas, 75237, United States

  • Study site

    Fort Worth, Texas, 76104, United States

  • Study site

    Garland, Texas, 75042, United States

  • Study site

    Lewisville, Texas, 75067, United States

  • Study site

    Mesquite, Texas, 75150, United States

  • Study site

    Paris, Texas, 75460, United States

  • Study site

    Round Rock, Texas, 78681, United States

  • Study site

    San Antonio, Texas, 78229, United States

  • Study site

    Southlake, Texas, 76092, United States

  • Study site

    Sugarland, Texas, 77479, United States

  • Study site

    Waco, Texas, 76712, United States

  • Study site

    Webster, Texas, 77598-4420, United States

  • Study site

    Salt Lake City, Utah, 84106, United States

  • Study site

    Christiansburg, Virginia, 24073, United States

  • Study site

    Seattle, Washington, 98133, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.